HER2低表达与HER2零表达乳腺癌新辅助化疗后的病理完全缓解、长期结局及复发模式
该回顾性研究纳入韩国Asan Medical Center 2014至2018年接受新辅助化疗及根治性手术的I-III期HER2低表达或HER2零表达乳腺癌患者,HER2零表达组818例、HER2低表达组754例。HER2零表达组病理完全缓解率更高(14.7% vs 9.8%,P=0.003),但按激素受体状态分层后无显著差异;HER2低表达组5年总生存和无病生存率更高,但在激素受体阳性组中无差异。作者认为 findings 不支持HER2低表达与HER2零表达乳腺癌生物学和临床特征不同,但HER2低表达的预后影响仍有争议,需进一步研究。
要点
- HER2零表达组病理完全缓解率14.7%,高于HER2低表达组的9.8%(P=0.003)。
- 按激素受体状态分层后,HER2状态与病理完全缓解率无显著差异(激素受体阳性P=0.4,激素受体阴性P=0.3)。
- HER2低表达组5年总生存和无病生存率高于HER2零表达组,但激素受体阳性组中无差异。
核心结论
- 作者认为 findings 不支持HER2低表达乳腺癌相比HER2零表达乳腺癌在接受新辅助化疗的患者中具有不同的生物学和临床特征。
- 作者指出HER2低表达状态在乳腺癌中的预后影响仍存在争议,因此需要进一步研究。
研究设计与样本
- 回顾性研究,在韩国首尔Asan Medical Center于2014年至2018年间连续纳入接受新辅助化疗并接受根治性手术的I-III期HER2低表达或HER2零表达乳腺癌患者。
- 共纳入HER2零表达组818例和HER2低表达组754例。
主要发现
- HER2低表达组激素受体阳性患者比例更高(81% vs 56%,P < 0.001)。
- HER2零表达组病理完全缓解率更高(14.7% vs 9.8%,P = 0.003)。
- 按激素受体状态分层后,激素受体阳性组(P = 0.4)和激素受体阴性组(P = 0.3)中HER2状态与病理完全缓解率均无显著差异。
- HER2低表达组5年总生存率和无病生存率更高(总生存P < 0.001;无病生存P = 0.002)。
- 在激素受体阳性组中,HER2状态与总生存和无病生存均无差异(总生存P = 0.21,无病生存P = 0.66)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The interest in HER2-low breast cancer (BC) has increased in recent years with the development of novel anti-HER2 antibody-drug conjugates. Here, we investigated the clinical outcomes and relapse patterns of patients with HER2-low or -zero BCs in an Asian population. METHODS: We retrospectively identified HER2-low or -zero BC patients with stage I-III tumours who were treated with neoadjuvant chemotherapy and underwent curative surgery, between 2014 and 2018 at Asan Medical Center, Seoul, Korea. RESULTS: A total of 818 and 754 HER2-zero and HER2-low BC patients, respectively, were consecutively included in this analysis. The HER2-low group had more hormone receptor [HR]-positive patients (81% versus 56%, P < 0.001). The HER2-zero group had a higher proportion of patients who achieved pathological complete response (pCR) (14.7% versus 9.8%, P = 0.003); however, no significant differences of pCR rate by HER2 status were identified in the HR-positive (P = 0.4) and HR-negative groups (P = 0.3) when analysed separately. The HER2-low BC cases had higher 5-year overall survival (OS) and disease-free survival (DFS) rates (P < 0.001 for OS; P = 0.002 for DFS); however, no differences were observed in terms of OS and DFS by HER2 status in the HR-positive group (P = 0.21 for OS and P = 0.66 for DFS). CONCLUSIONS: Our current findings do not support that HER2-low BC had different biology and clinical features compared to HER2-zero BC in patients who treated with neoadjuvant chemotherapy. However, the prognostic impact of HER2-low status in BC remains controversial; thus warranting further research.
引用
- Kang S, Lee SH, Lee HJ, et al. Pathological complete response, long-term outcomes, and recurrence patterns in HER2-low versus HER2-zero breast cancer after neoadjuvant chemotherapy. Eur J Cancer. 2022. PMID: 36183652. doi:10.1016/j.ejca.2022.08.031
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。